Drug Profile

Golimumab biosimilar - Bio-Thera Solutions

Alternative Names: BAT-2506

Latest Information Update: 09 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bio-Thera Solutions
Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
Mechanism of Action Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

Preregistration Psoriatic arthritis

Most Recent Events

27 Mar 2025 Ustekinumab biosimilar licensed to Dr Reddys Laboratories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam
11 Feb 2025 Golimumab biosimilar licensed to Accord BioPharma in USA
07 Feb 2025 Preregistration for Psoriatic arthritis in European Union (SC) prior to February 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com